Diagnosis & Differentiation
[The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma – An Expert Consensus Paper]
Pneumologie 2021 May 4 [Link] C Aigner, T Brüning, W E E Eberhardt, M Härter, H-P Kaelberlah, M Metzenmacher, R Shah, C Taube, M Thomas Abstract Asbestos-related mesotheliomas belong to the group of the most frequent occupational diseases in Germany, reaching about 1,000 new cases per year. The disease has a dismal prognosis because most…
Read MoreSarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases
International Journal of Surgical Pathology 2021 May 3 [Link] Diana M Oramas, Michael Zaleski, Cesar A Moran Abstract Sixty-four cases of sarcomatoid pleural mesothelioma represent the basis of this study. The patients are 51 men and 13 women between the ages of 42 and 79 years, who presented with symptoms of chest pain, cough, and…
Read MoreMesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Biomedicines 2021 April 7 [Link] Sören Weidemann, Pauline Gagelmann, Natalia Gorbokon, Maximilian Lennartz, Anne Menz, Andreas M Luebke, Martina Kluth, Claudia Hube-Magg, Niclas C Blessin, Christoph Fraune, Katharina Möller, Christian Bernreuther, Patrick Lebok, Till S Clauditz, Frank Jacobsen, Jakob R Izbicki, Kristina Jansen, Guido Sauter, Ria Uhlig, Waldemar Wilczak, Stefan Steurer, Sarah Minner, Eike Burandt,…
Read MoreA nontoxic dose of chrysotile can malignantly transform Met-5A cells, in which microRNA-28 has inhibitory effects
Journal of Applied Toxicology 2021 April 22 [Link] Fangfang Zhang, Xiuyuan Yuan, Hongjing Sun, Xianhong Yin, Yanan Gao, Min Zhang, Zhenyu Jia, Min Yu, Shibo Ying, Hailing Xia, Li Ju, Yun Xiao, He Tao, Jianlin Lou, Lijin Zhu Abstract Chrysotile, which is classified as a class I carcinogen by the International Agency for Research on…
Read MoreTranscriptomic alterations in malignant pleural mesothelioma cells in response to long‑term treatment with bullfrog sialic acid‑binding lectin
Molecular Medicine Reports 2021 June [Link] Takeo Tatsuta, Arisu Nakasato, Shigeki Sugawara, Masahiro Hosono Abstract Malignant pleural mesothelioma (MPM) is a universally lethal type of cancer that is increasing in incidence worldwide; therefore, the development of new drugs for MPM is an urgent task. Bullfrog sialic acid‑binding lectin (cSBL) is a multifunctional protein that has…
Read MoreTertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis
Virchows Archiv 2021 April 14 [Link] Nazim Benzerdjeb, Peggy Dartigues, Vahan Kepenekian, Séverine Valmary-Degano, Eliane Mery, Gerlinde Avérous, Anne Chevallier, Marie-Hélène Laverriere, Irène Villa, Olivier Harou, Françoise Galateau Sallé, Laurent Villeneuve, Olivier Glehen, Sylvie Isaac 8, Juliette Hommell-Fontaine, Frédéric Bibeau Abstract Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship…
Read MoreL1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumors, well-differentiated papillary mesothelial tumors and malignant mesotheliomas
Histopathology 2021 April 13 [Link] Georgia Karpathiou, Francois Casteillo, Maroa Dridi, Alexandra Papoudou-Bai, Jean Marc Dumollard, Michel Peoc’h Abstract Malignant mesothelioma (MM), the primary cancer of the mesothelium, is characterized by dismal prognosis. However, there are other forms of primary mesothelial tumors, which are benign, the adenomatoid tumors (AT) and the well-differentiated papillary mesothelial tumor…
Read MoreMalignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression
Clinical and Translational Oncology 2021 April 10 [Link] L Gutierrez-Sainz, P Cruz, S Martinez-Recio, O Higuera, M I Esteban-Rodriguez, F Arias-Lotto, R A Gonzalez, J De Castro-Carpeño Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management…
Read MoreMalignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression
Clinical and Translational Oncology 2021 April 10 [Link] L Gutierrez-Sainz, P Cruz, S Martinez-Recio, O Higuera, M I Esteban-Rodriguez, F Arias-Lotto, R A Gonzalez, J De Castro-Carpeño Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management…
Read MoreP14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
Frontiers in Oncology 2021 March 22 [Link] Federica Pezzuto, Francesca Lunardi, Luca Vedovelli, Francesco Fortarezza, Loredana Urso, Federica Grosso, Giovanni Luca Ceresoli, Izidor Kern, Gregor Vlacic, Eleonora Faccioli, Marco Schiavon, Dario Gregori, Federico Rea, Giulia Pasello, Fiorella Calabrese Abstract Introduction: The CDKN2A gene plays a central role in the pathogenesis of malignant pleural mesothelioma (MPM).…
Read More